Meeting
2014 Gastrointestinal Cancers Symposium
Second-line FOLFOX chemotherapy in patients with metastatic gallbladder cancer and cholangiocarcinoma.
Authors
Jose Luis Leal
Hematology and Oncology Department, Pontificia Universidad Catolica de Chile, Santiago, Chile
Jose Luis Leal , Juan Carlos Roa , Nicolas Jarufe , Jorge Madrid , Carolina Ibanez , Maria Elisa Herrera , Marcelo Garrido , Bruno Nervi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 322)
DOI
10.1200/jco.2014.32.3_suppl.322
Abstract #
322
Poster Bd #
C37
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world assessment of treatment sequencing of patients with advanced biliary tract cancer in a private practice in Rio de Janeiro and São Paulo, Brazil.
First Author: Ligia Carvalho
Poster
2021 ASCO Annual Meeting
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.
First Author: Nai-Jung Chiang
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
First Author: Jin Won Kim
First Author: Sebasti´n Mondaca